drugset / Trial / NCT06161090
Study of CM310 in Healthy Subjects
Non-randomizedSequentialQuadruple-blindTreatment
Summary
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.
Timeline
- Start
- 2019-09-03
- Primary completion
- 2020-01-13
- Completion
- 2020-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | CM310 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | CM310 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | CM310 | Monoclonal antibody | 600 mg | Subcutaneous |
Indications
No indication recorded.